RT Journal Article
SR Electronic
T1 Screening for Pathogenic Variants in Cardiomyopathy Genes Predicts Mortality and Composite Outcomes in UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.27.22276949
DO 10.1101/2022.06.27.22276949
A1 Asatryan, Babken
A1 Shah, Ravi A.
A1 Dabbagh, Ghaith Sharaf
A1 Landstrom, Andrew P.
A1 Darbar, Dawood
A1 Khanji, Mohammed Y
A1 Lopes, Luis R.
A1 Duijvenboden, Stefan van
A1 Muser, Daniele
A1 Lee, Aaron Mark
A1 Haggerty, Christopher M.
A1 Arora, Pankaj
A1 Semsarian, Christopher
A1 Reichlin, Tobias
A1 Somers, Virend K.
A1 Owens, Anjali T.
A1 Petersen, Steffen E.
A1 Deo, Rajat
A1 Munroe, Patricia B
A1 Aung, Nay
A1 Chahal, C. Anwar A.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/06/27/2022.06.27.22276949.abstract
AB Background Inherited cardiomyopathies can present with broad variation of phenotype. Data are limited regarding genetic screening strategies and outcomes associated with putative pathogenic variants (PuPV) in cardiomyopathy-associated genes in the general population.Objective We aimed to determine the risk of mortality and cardiomyopathy-related outcomes associated with PuPV in cardiomyopathy-associated genes in UK Biobank.Methods Using whole exome sequencing data, variants in dilated, hypertrophic and arrhythmogenic cardiomyopathy-associated genes with at least limited evidence of disease causality according to ClinGen Expert Panel curations, were annotated using REVEL (≥0.65) and ANNOVAR (predicted loss of function) to identify PuPVs. Individuals with PuPV comprised the genotype-positive (G+) and those without PuPV the genotype-negative (G-) cohorts. Group comparisons were made using time-to-event analyses for the primary (all-cause mortality) and secondary outcomes (diagnosis of cardiomyopathy; composite outcome of diagnosis of cardiomyopathy, heart failure, arrhythmia, stroke, and death).Results Among 200,619 participants, 22,401 (11.2%) were found to host ≥1 PuPV in cardiomyopathy-associated genes (G+). After adjusting for age and sex, G+ individuals had increased all-cause mortality [HR 1.07 (95%CI 1.02-1.13; p=0.011)] and increased rates of diagnosis of cardiomyopathy later in life [HR 2.37 (95%CI 1.98-2.85; p<0.0001)], which further increased in those with PuPV in definitive/strong evidence ClinGen genes [3.25 (95%CI 2.63-4.00; p<0.0001)]. G+ individuals had a higher risk of developing the composite outcome [HR 1.11 (95%CI 1.06-1.15; p<0.0001)].Conclusions Adults with PuPV in cardiomyopathy-associated genes have higher all-cause mortality and increased risk of developing cardiomyopathy-associated features and complications, compared to genotype-negative controls.Condensed Abstract Leveraging the UK Biobank prospective cohort, we analyzed whole exome sequencing data in dilated, hypertrophic and arrhythmogenic cardiomyopathy-associated genes using a population screening ‘genotype-first’ approach. Individuals with putative pathogenic variants in genes implicated in cardiomyopathies showed an increased risk of all-cause mortality, higher risk of developing clinical cardiomyopathy later in life, and higher risk of a composite outcome (cardiomyopathy, heart failure, arrhythmia, stroke, and death) compared to genotype-negative controls. These findings highlight the potential role of ‘genotype-first’ approach in elevating personalized medicine into population level precision health in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding support Dr. Asatryan is supported by Postdoctoral Research Fellowship Grant from the Gottfried und Julia Bangerter-Rhyner-Stiftung, Switzerland, the 2022 Research Fellowship for Aspiring Electrophysiologists from the Swiss Heart Rhythm Foundation, and Postdoc Mobility Fellowship from the Swiss National Science Foundation. Dr. Landstrom is supported by the National Institutes of Health (K08-HL136839, R01-HL149870, R01-EB032726), Doris Duke Charitable Foundation (CSDA-2020098), American Sudden Infant Death Syndrome Institute, John Taylor Babbitt Foundation, Hartwell Foundation, Additional Ventures, Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center. Dr. Darbar is supported by NIH/NHLBI R01 HL138737. Dr. Lopes is supported by an MRC UK Clinical Academic Partnership Award (CARP) MR/T005181/1. CMH is supported by the National Institutes of Health (R01HL141901). Dr. Semsarian is the recipient of a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (#1154992). Dr. Arora is supported by the NIH/NHLBI awards R01HL160982, R01HL163852, R01HL163081, and K23HL146887. Dr. Owens is supported by the Winkelman Family Fund for Cardiac Innovation. Drs. Petersen and Munroe acknowledge support from the National Institute for Health Research (NIHR) Biomedical Research Centre at Barts. The funders provided support in the form of salaries for authors as detailed above but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Drs. Somers and Chahal are supported by the Paul and Ruby Tsai Foundation and the National Institutes of Health (HL134885). Dr. Aung recognizes the National Institute for Health Research (NIHR) Integrated Academic Training programme, which supports his Academic Clinical Lectureship post. The funders had no input in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank received approval from the North West Multi-Centre Research Ethics Committee on June 17th, 2011 (Ref 11/NW/0382), which was extended on May 10th, 2016 (Ref 16/NW/0274) and extended on 18 June 2021 until 2026 (Ref 21/NW/0157) with written informed consent obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon accepted application to access the UK Biobank data.AFAtrial fibrillation or flutterARVCArrhythmogenic right ventricular cardiomyopathyCCDCardiac conduction diseaseCIEDCardiac implantable electronic deviceClinGenClinical Genome ResourceCMPCardiomyopathyDCMDilated cardiomyopathyFAFFiltering allele frequencyGCEPGene Curation Expert PanelHCMHypertrophic cardiomyopathyHFHeart FailurepLOFpredicted loss-of-functionPuPVPutative pathogenic gene variantUKBBUK BiobankWESWhole exome sequencing